Videos

Gandhi discussed examining social security disability rates and how SSD criteria may clash with a trait disease like fibromyalgia.

Troum discussed positive efficacy and safety findings from the phase 4 AGILE study.

Schett discussed findings from 2 early studies of CD19 CAR T-cell therapy.

Stone discussed findings from the first randomized, double-blind, placebo-controlled trial for IgG4-related disease.

Abdellatif discussed the importance of screening for osteopenia in patients with severe kidney disease.

Calabrese discussed considerations for patients with rheumatic disease diagnosed with COVID-19 and the virus’s role in promoting inflammation.

APAC President Laura Ross, PA-C, shares insights from the RhAPP conference, discussing autoimmune disease, cardiovascular risks, and the importance of interdisciplinary care.

Mease discussed the importance of comparator studies in a growing treatment landscape for PsA.

Calabrese discussed factors for rheumatologists to keep in mind, including recent travel and screening for viral infections.

Panelists discuss how their approaches to treating patients with rheumatoid arthritis focus on personalized strategies that prioritize achieving remission while carefully monitoring safety and efficacy outcomes.

Panelists discuss how the findings from the ORAL Surveillance study regarding cardiovascular and cancer risks associated with tofacitinib have influenced perceptions of JAK inhibitors, emphasizing the need to balance safety concerns with their efficacy in managing rheumatoid arthritis.

Calabrese discussed the multi-faceted role of viral infections in the field of rheumatology ahead of the 2024 CCR West meeting.

Nehad Soloman, MD, FACR; Andrew Sharobeem, DO, FACR, and Sunil Patel, MD, explore the nephrologist's vital role in gout diagnosis, treatment options for gout patients with chronic kidney disease, and strategies for managing refractory gout and its associated challenges.

Panelists discuss how continued cycling of tumor necrosis factor inhibitors (TNFis) without achieving remission can lead to complications like irreversible joint erosion, significantly diminishing patient quality of life, and explore why providers may persist with TNFis despite failure, access barriers to switching mechanisms of action, and treatment considerations for patients whose initial positive response to TNFis declines over time.

Panelists discuss how switching to a biologic with a different mechanism of action can enhance clinical outcomes in patients with inadequate responses to tumor necrosis factor inhibitors.

A key opinion leader discusses off-label treatments for fibromyalgia symptom management and promising ongoing studies, as well as mobile applications that can aid in monitoring and managing fibromyalgia symptoms.

Roy Morello, MD, discusses his team's research into the causes of poor pulmonary function among patients with osteogenesis imperfecta—better known as "brittle bone disease."

This interview at the Fall 2024 Maui Derm conference features Melodie Young, with a discussion about updates in psoriasis and psoriatic arthritis therapy for children.

Panelists discuss how the varying selectivity of JAK inhibitors—such as tofacitinib's broad inhibition of JAK1/JAK2/JAK3, baricitinib's inhibition of JAK1/JAK2, and upadacitinib's focus on JAK1—affects dose-related toxicity and overall treatment safety.

Panelists discuss how JAK inhibitors and TNF inhibitors differ in administration, efficacy, and safety due to their unique characteristics and mechanisms of action, with further variations in binding activities within the TNFi class impacting clinical outcomes.

Experts discuss the critical importance of early identification and consistent application of appropriate treatments for fibromyalgia patients to optimize their long-term health outcomes and quality of life.

Wells discussed the PrismRA blood test, which may benefit planning treatment regimens for patients with rheumatic disease.

Wells discussed the importance and recommended frequency for several factors, including lipid panels, chest X-rays, pregnancy tests, and flu vaccines.

This feature highlights the views of 3 experts on the integration of patient-reported outcomes into the management of psoriatic disease.

Mease went over research initiatives including the ARGO, AXIS, and STAR studies.

Nehad Soloman, MD, FACR; Andrew Sharobeem, DO, FACR, and Sunil Patel, MD, explore the nephrologist's vital role in gout diagnosis, treatment options for gout patients with chronic kidney disease, and strategies for managing refractory gout and its associated challenges.

Panelists discuss how head-to-head clinical trial data shape their treatment decisions, the significance of consistent remission rates across different patient populations, and the frequency with which remission data influence their choices to switch therapies.

Panelists discuss advanced treatment options for rheumatoid arthritis, focusing on the SELECT-COMPARE trial's head-to-head data of upadacitinib versus adalimumab, the use of upadacitinib in active RA refractory to biologics (SELECT-BEYOND trial), and the remission rates of upadacitinib compared to abatacept (SELECT-CHOICE trial).

An expert on fibromyalgia discusses concerns associated with long-term use of medications.

Mease discussed data supporting FDA approval for the indications in Fall 2024.